Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2551 to 2565 of 8236 results

  1. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]

    In development Reference number: GID-TA10979 Expected publication date:  11 March 2026

    Technology appraisal guidance
    In development

  2. Upadacitinib for treating giant cell arteritis [ID6299]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 4 February 2026.

    Technology appraisal guidance
    In consultation

  3. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 4 February 2026.

    Technology appraisal guidance
    In consultation

  4. Upadacitinib for treating giant cell arteritis [ID6299]

    In development Reference number: GID-TA11330 Expected publication date:  21 May 2026

    Technology appraisal guidance
    In development

  5. Gender Incongruence Services for Children and Young People

    In development Reference number: GID-QS10193 Expected publication date:  02 December 2026

    Quality standard
    In development

  6. Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [TSID12303]

    Awaiting development Reference number: GID-TA11929 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [TSID12299]

    Awaiting development Reference number: GID-TA11930 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Belzutifan for treating advanced pheochromocytoma or paraganglioma [TSID12304]

    Awaiting development Reference number: GID-TA11928 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Rare diseases

    In development Reference number: GID-QS10197 Expected publication date:  27 February 2026

    Quality standard
    In development

  10. DB-OTO for Hearing loss [TSID12321]

    Awaiting development Reference number: GID-TA11911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Etavopivat for treating sickle cell disease in people 12 years and over [TSID12320]

    Awaiting development Reference number: GID-TA11912 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [TSID12315]

    Awaiting development Reference number: GID-TA11913 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Perioperative care in adults

    In development Reference number: GID-QS10094 Expected publication date:  01 July 2026

    Quality standard
    In development

  14. Luspatercept for Anaemia due to myelodysplastic syndromes [TSID12310]

    Awaiting development Reference number: GID-TA11914 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Luspatercept for treating anaemia caused by myelofibrosis [TSID12309]

    Awaiting development Reference number: GID-TA11915 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development